Although the various members of the fibroblast growth factor (FGF) family are generally mitotic, one member, FGF18, has been shown to increase the rate of apoptosis of ovarian granulosa cells. In the present study, we first determined whether granulosa cells express FGF18 and we then explored the mechanism through which FGF18 increases apoptosis in vitro. Under culture conditions that favored estradiol secretion and CYP19A1 expression, granulosa FGF18 mRNA levels were barely detectable; however, withdrawing gonadotropic support (follicle-stimulating hormone or insulin-like growth factor 1) reduced levels of CYP19A1 mRNA and increased abundance of mRNA encoding the death ligand FASLG and FGF18. Addition of FGF18, but not FGF2, FGF10, or EGF, increased the proportion of apoptotic cells and frequency of caspase 3 activation, and these effects were abrogated by coculture with estradiol. Addition of FGF18 decreased abundance of mRNA encoding the antiapoptotic proteins GADD45B and MDM2, and increased that encoding the proapoptotic protein BBC3; these effects were reversed by coculture with estradiol. The physiological relevance of FGF18 was determined using an in vivo model: injection of FGF18 directly into growing bovine dominant follicles caused cessation of follicle growth by 24 h after injection. Collectively, these data demonstrate that FGF18 is proapoptotic in vivo and may act through a mechanism involving the BBC3-MDM2 pathway. apoptosis, caspase, estradiol, FGF, PUMA
INTRODUCTION
The fibroblast growth factors (FGFs) comprise a large family of proteins, most of which are secreted and act through transmembrane receptors [1] . These growth factors are generally mitogenic, and are critical for organ development and patterning in the developing embryo [2] . The FGF system is also active in the adult ovary, a site of constant tissue growth and remodeling. The most-studied FGF in the ovary is FGF2, and it has been localized to the theca cell layer in several species [3] [4] [5] . Although FGF2 inhibits steroidogenesis in granulosa cells [6] , it prevents apoptosis [7, 8] and stimulates proliferation [9, 10] . A similar role has been ascribed to FGF7 [11] and FGF1 [12] .
There is also evidence that some FGFs may possess proapoptotic activity, as an activating mutation of FGF receptor (FGFR) 3 caused infertility in mice at least in part through increased apoptosis of granulosa cells [13] . One FGF that activates FGFR3 is FGF18 [14] , which is expressed mainly in theca cells in the bovine ovary and at higher levels in atretic compared with healthy follicles in vivo [15] . Addition of FGF18 to bovine granulosa cells increases apoptosis as assessed by cell-cycle analysis and DNA fragmentation [15] . The mechanism of action of FGF18 is unclear, as it does not activate mitogen-activated protein kinase (MAPK)3/1 in bovine granulosa cells [16] .
Apoptosis in the ovary can follow the intrinsic or the extrinsic (death-receptor) pathway [17] . In the extrinsic pathway, activation of a death ligand receptor such as FAS [18] initiates a cascade of events that typically includes activation of an initiator caspase, such as caspase-8, and activation of proapoptotic proteins such as BAX, which cause the release of cytochrome c from mitochondria that in turn activates caspase-3 and apoptosis. BAX activity is regulated by a variety of intracellular proteins, including the prosurvival protein BCL2. Apoptosis in granulosa cells has been associated with increased abundance of the tumor suppressor protein p53 (product of the TP53 gene) [19] , which acts transcriptionally to regulate the expression of genes encoding apoptotic proteins including BAX and p53 upregulated modulator of apoptosis (PUMA, gene symbol BBC3), cell cycle proteins including p21 (product of the CDKN1A gene), and proteins associated with DNA repair such as the growth arrest and DNA-damageinducible 45 (GADD45) family (reviewed in [20] ). Activity of proteins in the p53 family is negatively regulated by the antiapoptotic protein mouse double minute 2 (MDM2) [20] . Apoptosis in ovarian cells has also been associated with increased activity of p38 (product of the MAPK14 gene) [21, 22] , which interacts with GADD45 proteins to enhance or reduce apoptosis depending on cell context [23] .
The role of FGF18 in follicle apoptosis remains unclear. Messenger RNA encoding FGF18 was detected in atretic but not healthy bovine granulosa cells [15] but it is not known if this is a cause or consequence of apoptosis. In the first objective of the present report, we test the hypothesis that the induction of granulosa cell atresia by withdrawal of gonadotropic support [24] will increase FGF18 mRNA levels. Secondly, as FGF18-stimulated apoptosis is associated with decreased GADD45B mRNA levels [15, 16] , we tested the hypothesis that FGF18 increases apoptosis through components of the TP53 or MAPK14 pathway.
MATERIALS AND METHODS

Cell Culture
The granulosa cell culture was based on that described by Gutiérrez et al. [25] and maintained an estrogenic phenotype with a minimum of luteinization [26] . The reagents were obtained from Invitrogen except where otherwise stated. Briefly, ovaries of adult cows were collected irrespective of stage of estrous cycle from a local abattoir and follicles between 2 and 5 mm diameter were dissected from the ovarian stroma. Follicles were bisected in Dulbecco modified Eagle medium/F12 (DMEM/F12) and granulosa cells were collected by rinsing the follicle walls with DMEM/F12. The basal medium for all cultures was DMEM/F12 with added sodium bicarbonate (10 mM), sodium selenite (4 ng/ml), bovine serum albumin (BSA; 0.1%; Sigma-Aldrich), penicillin (100 U/ml), streptomycin (100 lg/ml), transferrin (2.5 lg/ml), nonessential amino acid mix (1.1 mM), and androstenedione (A4; 10 À7 M at start of culture and 10 À6 M at each medium change). A viable cell count was performed in the presence of 0.4% trypan blue, and 1 3 10 6 viable cells/ml were cultured in 24-well plates at 378C in 5% CO 2 in air for 6 days, with 700 ll medium being replaced every 2 days unless otherwise stated.
To measure steroid secretion, the medium was removed for steroid assay on Day 6 and stored at À208C. To measure mRNA abundance, cells were collected into TRIzol and stored at À808C until RNA extraction. All series of cultures were performed on at least three different pools of cells collected on different occasions.
Experimental Design-Expression of FGF18
To assess the regulation of FGF18 mRNA abundance, granulosa cells were cultured under normal conditions followed by gonadotropin ''withdrawal'' to simulate the environment of regressing/atretic follicles. In the first experiment, cells were cultured in medium containing insulin (10 ng/ml) from Day 0, the standard dose in this model [15] , and then from Day 2 cells were treated 1) with follicle-stimulating hormone (FSH; 1 ng/ml; AFP-5332B; NIDDK; estrogenic control cells), 2) without FSH to mimic a low-gonadotropin environment, 3) without FSH and with replacement of A4 with the nonaromatizable substrate dihydrotestosterone (DHT) to ensure minimal estradiol secretion, and 4) with DHT and exogenous estradiol (100 ng/ml), a known prosurvival factor. In the second experiment, cells were cultured in medium containing a lower dose of insulin (1 ng/ml) for 2 days, followed by 2 days in medium supplemented with FSH (1 ng/ml) and insulin (1 ng/ml). On Day 4, the medium was completely removed and replaced with medium devoid of insulin-like growth factor (IGF) 1 or insulin to mimic withdrawal of gonadotropic support, or with medium supplemented with IGF1 analog (10 ng/ml; LR3, Sigma-Aldrich) or insulin (10 ng/ml) to mimic increased gonadotropic support.
Experimental Design-Effects of FGF18
To assess effects of FGF on apoptosis, cells were cultured in medium supplemented with insulin (10 ng/ml) for 2 days, followed by medium containing FSH (1 ng/ml) and insulin (10 ng/ml) for 4 days to allow development of estrogenic cells. Recombinant human FGF2, FGF10, FGF18 (PeproTech), or EGF (Sigma-Aldrich) was added at 10 ng/ml for the final 2 days; these doses were chosen as they have previously been shown to impact granulosa function in this cell culture system [15, 27, 28] . Subsequent experiments were conducted with FGF18 or FGF2 and with and without estradiol (20 ng/ml; concentrations typically achieved after 6 days culture) as treatments. At the end of culture, cells were recovered for assessment of apoptosis by flow cytometry or caspase-3 activation (described below).
The effect of FGF18 on MAPK14 phosphorylation was measured by culturing cells as described above and addition of 10 ng/ml FGF18 or FGF2 on Day 5 of culture. Cell lysates were collected from cells at 0, 15, 30, 60, and 120 min after treatment, and used for immunoblot analysis as described below.
The effect of FGF18 on granulosa mRNA abundance was determined by culturing cells for 6 days in medium containing insulin and FSH (10 ng/ml each to maximize FGFR expression [15] ), with the addition of FGF18 or FGF2 (10 ng/ml) from Day 2 of culture, with or without exogenous estradiol (20 ng/ml). At the end of culture, the medium was removed and total RNA was extracted using TRIzol according to the manufacturer's instructions.
Animals and Intrafollicular Injection
All experimental procedures using cattle were reviewed and approved by the Universidade Federal de Santa Catarina Animal Care and Use Committee. Cycling crossbred heifers (Bos taurus taurus 3 B. taurus indicus) with a body condition score of 3 or 4 on a scale from 1 (thin) to 5 (obese) were used in this study. The experiment was performed in spring.
Estrous cycles were synchronized with injection of two doses of prostaglandin F2a (PGF2a) analog (cloprostenol; 125 lg i.m.; Ourofino Agronegócio) 12 h apart. Eight heifers were observed in estrus 2-5 days after PGF2a, and the experiment was performed during the first follicular wave of the cycle. Ovaries were examined once a day by transrectal ultrasonography using an 8-MHz linear-array transducer (Mindray M5 Vet; Shenzhen Mindray Bio-medical Electronics Co., Ltd.) and all follicles larger than 5 mm were recorded on three virtual slices of the ovary, allowing a three-dimensional localization and monitoring of individual follicles during the follicular wave. The day of follicular emergence was retrospectively identified as the last day on which the dominant follicle was 4 or 5 mm in diameter [29] . The day of divergence was identified as the first day on which there was a difference in diameter of at least 1 mm between the largest and second-largest follicles.
When the largest follicle of the growing cohort reaches a diameter larger than 7 mm it is reliably identifiable as the future dominant follicle [30] . Following identification, the follicle was injected with PBS (n ¼ 3) or FGF18 (PeproTech; n ¼ 5) diluted in PBS to a final concentration of 1 lg/ml. Intrafollicular injections were performed with a double-needle system and guided by ultrasound as described in detail [31] ; under epidural anesthesia, the needle was guided through the vaginal wall, and the ovary manipulated transrectally to allow the needle to penetrate the follicle through the ovarian stroma at the base of the follicle. The injection volume was calculated based on the volume of follicular fluid estimated by the linear regression equation V ¼ À685.1 þ 120.7D, where V is the estimated follicular volume and D is the diameter of the follicle to be injected [31] . The volume administered corresponded to approximately one tenth of total follicular fluid volume. The mean follicle diameter at time of injection was 8.8 6 0.8 mm in the control group and 7.7 6 0.4 mm in the treatment group (not significantly different). Two hours after the injections, follicles were examined by ultrasonography to ensure that no follicle damage occurred as a result of the injection, as a reduction in diameter larger than 1 mm within 2 h of injection is evidence of follicle leakage. Animals were monitored daily for 3 consecutive days by ultrasonography to evaluate the effect of FGF18 on follicle growth.
Real-Time RT-PCR
Gene expression was assessed by relative real-time RT-PCR. Total RNA (1 lg) was first treated with 1 U DNase (Invitrogen) to digest any contaminating DNA. The RNA was reverse transcribed in the presence of 1 mM oligo(dT) primer and 4 U Omniscript RTase (Qiagen) according to the manufacturer's instructions.
Real-time PCR was conducted in an ABI Prism 7300 instrument (Applied Biosystems) with Power SYBR Green PCR Master Mix (Applied Biosystems) and bovine-specific primers for amplifying histone H2AFZ [15] 0 , reverse 5 0 -AAGGGCAGGAGTCCCATGAT-3 0 ) cDNA. Primers for BBC3 were designed to encompass the BH3 domain and thus measure transcripts that give rise to biologically active forms of the protein [36] , and the primers of each gene were located on either side of an exon boundary. Common thermal cycling parameters (3 min at 958C and 40 cycles of 15 sec at 958C, 30 sec at 608C, and 30 sec at 728C) were used to amplify each transcript. Product identity was verified by sequencing, and melting curve analyses were performed in all PCR runs to verify generation of single amplicons. Samples were run in duplicate, and were expressed relative to H2AFZ as housekeeping gene, which was stable under the culture conditions used. Data were normalized to a calibrator sample using the DDCt method with correction for amplification efficiency [37] . Average coefficients of variation were 0.4% and 16% for Ct and ddCt values, respectively.
Assessment of Apoptosis
Cell death and apoptosis in cultured cells was measured by flow cytometry and immunofluorescence for cleaved caspase-3. Flow cytometry was performed essentially as described [38] . After culture, cells were recovered by scraping the plate with a rubber spatula. The cells were washed three times in ice-cold PBS, then fixed overnight in 70% ethanol before staining with propidium iodide (50 mg/ml in PBS with 0.1% Triton X and 20 mg/ml RNase A). A minimum of 25 000 propidium iodide-stained cells/sample were sorted on a FACSVantage SE (BD Biosciences) and analyzed with Cell Quest Pro software (BD Biosciences). The number of cells in the ''sub-G1'' peak was quantified and represented the number of dead (apoptotic) cells.
For immunofluorescence, cultured cells were fixed in 4% paraformaldehyde for 20 min, washed sequentially in 2% Triton-X and 0.05% Tween, blocked in PORTELA ET AL.
0 ,6-diamidino-2-phenylindole (DAPI). Cells were examined with a Leica epifluorescent microscope, digital images were captured, and mean fluorescence intensities in each field for Cy3 and DAPI were quantified with ImageJ software (NIH). Results are expressed relative to DAPI. Cleaved caspase-3 abundance was consistent with flow cytometric assessment of apoptosis in granulosa cells in a previous study [35] .
Immunoblotting
Granulosa cells were treated with FGF18 for 0, 15, 30, 60, and 120 min, washed with ice-cold PBS, and lysed in 50 ll/well ice-cold RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, and protease inhibitor cocktail). The homogenate was centrifuged at 6000 3 g for 5 min at 48C and the supernatant stored at À808C. Protein concentrations were determined by BCA protein assay (Pierce). Samples (15 lg total protein) were loaded onto 10% SDSpolyacrylamide gels in SDS loading buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% b-mercaptoethanol, 12.5 mM EDTA, and 0.02% bromophenol blue), electrophoresed, and electrotransferred to Hybond-P polyvinylidene fluoride membrane (GE Amersham) in 39 mM glycine, 48 mM Tris-base, 1% SDS, 20% methanol, pH 8.3. After transfer, the membranes were blocked in 5% nonfat dry milk in TTBS (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.5) for 1 h. Membranes were incubated overnight with primary antibodies against phospho-MAPK14 (cat #9215, 1:1000), total MAPK14 (cat #9211; 1:1000; Cell Signaling Technology), or COX4I1 (sc-69359, 1:1000; Santa Cruz Biotech) diluted in TTBS. After washing three times with TTBS, membranes were incubated for 1 h at room temperature with 1:10 000 anti-rabbit (GE Healthcare Canada) or anti-goat (Santa Cruz) HRPconjugated IgG diluted in 5% nonfat dry milk in TTBS. The protein bands were visualized by chemiluminescence (ECL; Millipore) and quantified using a Vilber Lourmat Fusion Fx chemiluminescence detection system. Phospho-MAPK14 levels were expressed relative to total MAPK14 or COX4I1 levels.
Steroid Assay
Estradiol was measured in spent culture medium as previously described [39] with an antibody raised in rams [40] . Samples were measured in a single assay with an intra-assay coefficient of variation of 7%. The sensitivity of the assay was 0.2 ng/ml.
Statistics
Proportions of cells in stages of the cell cycle were arcsine transformed before analysis. Other data that did not follow a normal distribution (ShapiroWilk test) were transformed to logarithms. Homogeneity of variance was tested with O'Brien and Brown-Forsythe tests. Analysis of variance was performed with JMP software (SAS Institute) with treatment as main effect and culture replicate as a random variable in the F-test. Differences between means were tested with Fisher protected least significant difference test or by Dunnett test for specific comparisons with controls. In vivo follicle growth data were analyzed by repeated-measures ANOVA and comparisons of growth rates at specific times were performed by t-tests. Data are presented as means 6 SEM.
RESULTS
Regulation of FGF18 Expression in Granulosa Cells
When granulosa cells were cultured in the presence of FSH, mRNA encoding FGF18 was detected at very low levels, with samples reaching threshold only at 39 cycles. Culture without FSH resulted in an atretic phenotype judged by barely detectable CYP19A1 mRNA and elevated FASLG mRNA abundance (Fig. 1A) ; under these conditions, FGF18 mRNA levels were significantly increased, with threshold values reached at 36 cycles. Replacing A4 with DHT resulted in similar gene expression profiles, and addition of estradiol to DHT-treated cells did not alter FGF18 or FASLG mRNA abundance. As the medium without FSH contained 10 ng/ml insulin, which can be gonadotropic, we then cultured cells under conditions of even lower gonadotropic support (1 ng/ml insulin) before treatment for 2 days with a higher dose of insulin, with IGF, or with neither. Supplementation with either IGF or insulin resulted in low levels of FGF18 mRNA (Fig.  1B) , as did culture with FSH above. However, removal of insulin and IGF1 for 2 days resulted in a 20-fold increase in FGF18 mRNA abundance (Fig. 1B ). These data demonstrate that FGF18 mRNA levels are increased when granulosa cells are placed in conditions that decrease CYP19A1 mRNA abundance and increase FASLG mRNA abundance, and that
FIG. 1. Regulation of FGF18 mRNA abundance in granulosa cells in vitro.
A) Granulosa cells were cultured under serum-free conditions in the presence of insulin (10 ng/ml) from Day 0 and cultured with or without FSH (1 ng/ml) and replacement of A4 with DHT (10 À7 M) and addition of estradiol (100 ng/ml) for 4 days starting on Day 2. B) Granulosa cells were cultured for 2 days with insulin (1 ng/ml), followed by 2 days with FSH (1 ng/ml) and insulin (1 ng/ml), followed by a test period of 2 days with IGF1 (10 ng/ml), insulin (10 ng/ml), or neither (withdraw). Steady-state mRNA levels were measured by real-time PCR and expressed relative to a calibrator sample in the control group (þFSH or IGF1) with the DDCt method. Data are means 6 SEM of three independent cultures; bars with asterisks (A) indicate means that are different (P , 0.05) from the control with FSH (Dunnett test), and bars with no common letters (B) are significantly different from each other (Fisher, P , 0.05).
FGF18 AND GRANULOSA APOPTOSIS estrogen signaling is not involved in the regulation of FGF18 mRNA levels.
Effect of FGF18 on Follicle Growth In Vivo
To determine the impact of FGF18 on follicle growth in vivo, the growing first-wave dominant follicle was injected with FGF18 and the fate of the follicle was followed by ultrasound imaging for 72 h. Control follicles injected with PBS continued to grow, whereas follicles injected with FGF18 regressed, and the difference in diameter between control and treated follicles was significant by 24 h after injection (Fig. 2) .
Effect of FGF18 on Apoptosis
As we had previously demonstrated that FGF18 increased the proportion of apoptotic cells as measured by cell cycle analysis [15] , we then determined whether other related ligands also altered apoptosis. Treatment of cells with FGF18 increased (P , 0.05) the proportion of cells in the sub-G1 peak, whereas treatments with the same concentration of FGF2, FGF10, or EGF were without effect (Fig. 3A) . To test the role of estradiol, a known prosurvival factor, cells were treated with FGF18 with and without estradiol; FGF18 increased the proportion of cells in the sub-G1 peak, and this increase was abrogated by the presence of estradiol (Fig. 3B) .
These effects were then confirmed by immunofluorescent detection of cleaved caspase-3 as an alternative measure of apoptosis; FGF18 increased (P , 0.05) cleaved caspase-3 protein levels, and cotreatment with estradiol completely abrogated this response (Fig. 4) . Treatments with estradiol alone or with FGF2 did not alter caspase-3 activation (Fig. 4) .
Effect of FGF18 on Apoptosis-Related Pathways
A time-course study was performed to determine the effect of FGF2 and FGF18 on MAPK14 activation. Addition of FGF2 caused an increase in phospho-MAPK14 at 60 and 120 min, whether expressed relative to total MAPK14 or COX4I1 protein (Fig. 5) . Addition of FGF18 increased abundance of both total and phosphorylated MAPK14, such that the ratio did not change; however, when expressed relative to COX4I1, FGF18 increased phospho-MAPK14 at 60 and 120 min (Fig.  5) .
Attempts to measure TP53 protein levels were not successful; therefore, we targeted genes known to be implicated in the TP53 pathway. Treatment with FGF18 or FIG. 2 . Effect of FGF18 on follicle growth in vivo. FGF18 (n ¼ 5) or PBS (n ¼ 3) was injected into the growing dominant follicle of a follicle wave, and follicle growth was measured by ultrasound imaging. A) Follicle diameters for 72 h after injection. B) The 24-h growth rates of the injected follicles at each of the 3 days after treatment. Data are means 6 SEM, and asterisks denote significant differences between control and FGF18 treatments (P , 0.05).
FIG. 3. Effect of
FGFs on granulosa cell survival in vitro. Granulosa cells were cultured under serum-free conditions for 2 days with insulin (10 ng/ ml), followed by 4 days with FSH (1 ng/ml) and insulin (10 ng/ml), and with addition of the factors shown (10 ng/ml each; A) or addition of FGF18 (10 ng/ml) with and without estradiol (E2; 20 ng/ml; B) for the final 2 days culture. The proportion of cells in the sub-G1 phase of the cell cycle was measured by fluorescence-activated cell sorting. Data are means 6 SEM of three independent cultures. Asterisks (A) indicate means that are different (P , 0.05) from the control (Dunnett test), and bars with no common letters (B) are significantly different (Fisher, P , 0.05). C, control.
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FGF2 inhibited estradiol secretion (Fig. 6) as expected, and treatment of cells with FGF18 significantly inhibited GADD45B, MDM2, and MTBP mRNA levels, increased those of BBC3 (Fig. 6) , and had no effect on BAX (Fig. 6) , FASLG, TP53, or CDKN1A (not shown) mRNA abundance. Addition of sufficient exogenous estradiol to maintain levels similar to those in controls abrogated the effect of FGF18 (Fig. 6 ), whereas treatment with estradiol alone did not alter abundance of any gene measured. FGF2 significantly increased GADD45B and BBC3 mRNA levels (Fig. 6, white bars) .
DISCUSSION
Although most FGFs are mitogens, we previously described a proapoptotic action of FGF18 on bovine granulosa cells in vitro [15] . In the present study we explored the regulation of FGF18 mRNA abundance by granulosa cells and the mechanism of action of FGF18 on granulosa cells. Collectively the data suggest that FGF18 is a potential theca-derived protein that is produced in response to a low-gonadotropin environment and that increases granulosa cell apoptosis via a mechanism that can be abrogated by estradiol.
Although we previously reported that FGF18 mRNA is expressed mainly in the theca cell layer of atretic follicles, we also noted a small but significant increase in mRNA levels in granulosa cells from atretic follicles [15] . We explored this observation further in the present study, and confirmed that FGF18 mRNA levels in granulosa cells are very low when cells are cultured under conditions that promote estrogen biosynthesis, which is a hallmark of follicle health [41] . A reduction in gonadotropin support caused an increase in signs of atresia (decreased CYP19A1 mRNA levels and increased FASLG mRNA levels) and a concomitant increase in FGF18 mRNA levels, in agreement with our previous observation in atretic follicles [15] . Withdrawal of FSH or IGF1/insulin support decreased estradiol secretion, and estradiol is known to have antiapoptotic effects on granulosa cells [42] ; however, exogenous estradiol did not reverse the effects of gonadotropin withdrawal, indicating that FGF18 mRNA is not directly regulated by estradiol. Abundance of FGF18 mRNA appeared to be considerably lower in granulosa cells compared with theca cells, and notwithstanding the difficulties of comparing between cell types, we concluded that increased FGF18 mRNA in apoptotic granulosa cells is more likely to be a consequence of stress/apoptosis rather than the cause.
Several lines of evidence indicate that FGF18 increases the incidence of apoptosis in granulosa cells in vitro, including an increase in DNA fragmentation [15] , and with the present data we extend this to demonstrate that FGF18 increases caspase-3 activation. Two critical questions remain about these effects of FGF18: are they specific to FGF18, and are they relevant to follicle function in vivo? Both these questions have been answered in the present study. First, neither FGF2 nor FGF10 altered the proportion of apoptotic cells or the activation of caspase-3, indicating that this is a specific action of FGF18 and not a broad effect of FGFs in general. Second, direct injection of FGF18 into a growing follicle in vivo caused regression of that follicle. The regression of the follicle was not an artifact of injection, as saline-injected control follicles did not regress, and our previous studies using this model have demonstrated that   FIG. 4 . Effect of FGF18 on caspase-3 activation in bovine granulosa cells in vitro. Granulosa cells were cultured in serum-free medium containing FSH and insulin (10 ng/ml) for 6 days and treated with FGF18 or FGF2 (10 ng/ml) with and without E2 (20 ng/ml) for the last 4 days of culture. Cleaved caspase-3 was detected by immunofluorescence, and fluorescence intensity was expressed relative to cell number (DAPI fluorescence). Original magnification 3200. Images from one replicate are shown, and data are means 6 SEM of three independent cultures. An asterisk indicates that the mean is different (P , 0.05) from the control (Dunnett test).
FGF18 AND GRANULOSA APOPTOSIS injection of the nonapoptotic peptide angiotensin II had no effect on the growth of a developing follicle [30] . Therefore FGF18 is capable of increasing granulosa cell apoptosis and causing follicle regression.
The mechanism(s) by which FGF18 acts on granulosa cells are unknown, as it does not stimulate expression of typical FGF target genes [16] and does not cause the rapid and transient increase in MAPK3/1 activation observed with FGF2 [34] . In the present study, FGF2 and FGF18 resulted in similar increases in the abundance of phosphoMAPK14. This observation is important for two reasons: it marks the first identification of a common intracellular pathway used by FGF18 and the prototypic FGF2, and it suggests that MAPK14 is not the main determinant of the proapoptotic actions of FGF18.
Another major apoptotic pathway involves TP53, and although we were unable to measure TP53 protein levels, we observed that FGF18 increased the abundance of mRNA encoding the TP53 target gene, BBC3, and that estradiol abrogated this effect. The direction of change of BBC3 mRNA levels is entirely consistent with the effects of FGF18 and estradiol on caspase-3 activation and the incidence of apoptosis. An inhibitory effect of estradiol on BBC3 expression has also been observed in breast cancer cells and the ischemic hippocampus [43, 44] .
In healthy cells, the activity of members of the p53 family are kept under control by proteins that include GADD45B, MDM2, and the MDM2-binding protein, MTBP; inhibition of MDM2 increased apoptosis and BBC3 mRNA levels in cancer cells [45] , and both MTBP and GADD45B enhance the activity of MDM2 [46, 47] . The inhibition of MDM2, MTBP, and GADD45B mRNA levels by FGF18 in the present study is therefore consistent with a role for this FGF in modulating the TP53-BBC3 pathway to apoptosis. Interestingly, estradiol has been shown to increase MDM2 mRNA levels in human hepatocytes and breast cancer cells [48, 49] , and in the present study estradiol increased MDM2, MTBP, and GADD45B mRNA levels in FGF18-treated cells, consistent with its effect on apoptosis. Collectively, these data implicate FGF18 in a pathway that involves BBC3-mediated apoptosis.
In some cell types, FGF2 acts in part by downregulating BBC3 and upregulating MDM2 [50] [51] [52] . This was not the case in granulosa cells in the present study, as FGF2 did not alter MDM2 transcript levels and paradoxically increased BBC3 mRNA levels. However, FGF2 also resulted in increased expression of the survival factor GADD45B ( [34] and present study) that may mitigate the effects of increased BBC3 levels. In contrast to the inhibitory effect of estradiol on FGF18-stimulated BBC3 mRNA levels, estradiol did not reduce FGF2-stimulated BBC3 mRNA abundance. Although these measurements are of mRNA and do not necessarily reflect changes in protein levels, these incoherent effects of FGF2 on apoptosisrelated genes stand in contrast to the consistent effects of FGF18.
FIG. 5.
Effect of FGF2 and FGF18 on MAPK14 phosphorylation in bovine granulosa cells in vitro. Cells were cultured in serum-free medium containing FSH and insulin (10 ng/ml each) for 5 days and treated with FGF18 or FGF2 (10 ng/ml each) for the times shown. Total cell extracts were used for Western blotting with MAPK14, phospho-MAPK14, or COX4I1 antibodies. Data are mean (6SEM) ratios of phospho-MAPK14 to total MAPK14 or COX4I1 (n ¼ 4). Bars without common letters are different (P , 0.05; Tukey-Kramer). Images from one replicate are shown, with molecular mass markers for MAPK14 (kDa).
In conclusion, the present data provide novel evidence that FGF18 is a theca-derived factor that induces or enhances follicle atresia, at least in cattle. We propose that FGF18 activates FGFR(s) on granulosa cells and through as yet unknown pathways results in the upregulation of the proapoptotic factor BBC3, which in turn leads to the activation of the caspase cascade, apoptosis, and follicle regression.
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